Spatial Configuration of Residual Pancreatic Cancer Is Associated with Recurrence Risk

The tumor-stroma spatial topology of residual pancreatic cancer carries prognostic information independent of standard clinicopathologic factors. Prior prognosis relied mainly on pathologic response grading and residual tumor burden, whereas this work adds spatial composition (patch density, edge density) and configuration (compactness/complexity, intermixing) quantified from routine H&E slides. Retrospective cohort of 203 patients, all treated with neoadjuvant therapy and curative-intent resection and restricted to minor pathologic response, with multivariable models adjusted for standard clinicopathologic factors; the two spatial risk models yielded adjusted HRs of 1.71 (P = 0.003) and 2.19 (P = 0.002).

The spatial risk models stratified outcomes in cases where pathologic response grading and residual cancer area did not. This suggests that within the traditionally heterogeneous 'minor response' group, spatial configuration offers additional discriminatory ability. The text states that both models 'stratified outcomes in which pathologic response grading and residual cancer area did not,' indicating the stratification is presented in comparison with existing measures.

High-risk spatial configurations are associated with an immune-excluded phenotype, providing a cellular immune correlate for spatial risk. It links slide-level spatial metrics to the spatial distribution of tumor-infiltrating lymphocytes rather than remaining a purely morphologic description. High-risk configurations were accompanied by reduced intratumoral TIL density and infiltration ratio, with relative TIL accumulation at the cancer periphery and within stroma, described in the text as 'consistent with an immune-excluded phenotype.'

The results apply to patients with pancreatic ductal adenocarcinoma who received neoadjuvant therapy and curative-intent resection and whose pathologic response was only minor; spatial metrics are obtainable from routine H&E whole-slide images with an AI segmentation pipeline. Their value lies in offering additional risk discrimination for a group that has been hard to stratify, and in motivating studies of spatially informed adjuvant strategies.

A careful reader would still watch: the robustness of spatial metrics across scanners, staining batches, and segmentation pipelines; the reproducibility of the two risk models in external cohorts; whether the association between spatial configuration and the immune-excluded phenotype is accompanying or causal; and whether these metrics can actually change adjuvant treatment decisions. In addition, this summary is based on abstract-level text only, without figures or supplementary materials; if those contain thresholds, calibration, or subgroup information, they could affect judgment about the models' usability.